treatment protocol to follow with drugs and dosage in detail for tcc in dogs
Reading File
Finding Sources
Searching PubMed
transitional cell carcinoma dog treatment protocol
Searching the Web
canine TCC bladder cancer treatment protocol drugs dosage 2024 veterinary oncology
Reading Web Page
https://vet.purdue.edu/wcorc/cancer-research/canine-urinary-…
Searching PubMed
canine bladder TCC piroxicam mitoxantrone vinblastine treatment
Here is the complete, detailed treatment protocol for Transitional Cell Carcinoma (TCC) in dogs, based on Purdue University's Comparative Oncology Program (a leading authority on canine TCC), veterinary oncology literature, and current clinical practice.
Canine TCC (Transitional Cell Carcinoma) - Treatment Protocol
Overview
TCC (now also called urothelial carcinoma) is the most common urinary tract tumor in dogs. It is highly invasive and most commonly located at the bladder trigone (the neck of the bladder near the ureters and urethra), which makes surgery usually impossible. Treatment is primarily medical - with drugs. Median survival with treatment ranges from 6-12 months depending on protocol.
High-risk breeds: Scottish Terrier, Shetland Sheepdog, Beagle, West Highland White Terrier, Wire Fox Terrier
Step 1: Baseline Workup Before Starting Treatment
Before initiating any protocol, obtain:
- Complete blood count (CBC), serum chemistry panel, urinalysis
- Abdominal ultrasound (tumor location, ureteral involvement, lymph node status)
- Thoracic radiographs (3 views) to rule out lung metastasis
- Abdominal CT scan (preferred over ultrasound for full staging)
- Urine BRAF mutation test (if available) - supports diagnosis
- Biopsy/cytology for definitive histopathology (preferred via traumatic catheterization or cystoscopy - avoid transabdominal FNA due to seeding risk)
Step 2: Staging
| Stage | Description |
|---|---|
| T1 | Tumor invades subepithelial connective tissue |
| T2 | Tumor invades muscle |
| T3 | Tumor invades adjacent organs (prostate, vagina) |
| N0/N1 | No/with regional lymph node involvement |
| M0/M1 | No/with distant metastasis |
Most dogs present at T2 or T3. ~20% have regional LN involvement; ~15-25% have distant metastasis at diagnosis.
Step 3: Treatment Protocols (by line)
FIRST-LINE PROTOCOL (Preferred Starting Treatment)
Protocol 1A: Vinblastine + Piroxicam (Current Standard of Care at Purdue)
This is now considered the first-line protocol of choice based on Purdue University studies showing the highest response rates.
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Vinblastine | 2 mg/m² | IV (slow bolus or infusion) | Every 2 weeks |
| Piroxicam | 0.3 mg/kg | PO with food | Once daily |
- Response rate: 58% partial remission, 33% stable disease, 8% progressive disease
- Median survival: 299 days (range 21-637 days)
- Vinblastine side effects: Myelosuppression (check CBC before each dose), mild GI signs, perivascular necrosis if extravasated - must give via a clean IV catheter
- Piroxicam side effects: GI ulceration, renal toxicity
Monitoring:
- CBC 7-10 days after each vinblastine dose (neutrophil nadir)
- Serum chemistry (BUN, creatinine) every 1-2 months
- Abdominal ultrasound every 6-8 weeks to assess response
Dose reductions for vinblastine:
- If ANC < 1,500/µL at time of treatment: delay 1 week
- If ANC nadir < 500/µL: reduce dose to 1.5 mg/m²
Protocol 1B: Piroxicam Alone (for owners who decline IV chemotherapy)
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Piroxicam | 0.3 mg/kg | PO with food | Once daily |
- Response rate: 20% partial/complete response (Knapp 1994)
- Median survival: ~244 days
- A reasonable option with good quality of life
- Add misoprostol (1-3 mcg/kg PO q8-12h) or a proton pump inhibitor (omeprazole 0.7-1 mg/kg PO q24h) to protect against GI ulceration
Note: Meloxicam (0.1 mg/kg PO q24h after a 0.2 mg/kg loading dose) may be substituted for piroxicam as it has similar COX-2 inhibitory properties, though less clinical data exists for TCC specifically.
SECOND-LINE PROTOCOL
Protocol 2A: Mitoxantrone + Piroxicam
Previously considered the "protocol of choice" before vinblastine data - still widely used and effective, particularly when vinblastine fails.
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Mitoxantrone | 5 mg/m² | IV (slow infusion over 10-15 min) | Every 3 weeks |
| Piroxicam | 0.3 mg/kg | PO with food | Once daily |
- Response rate: ~35% remission; ~46% stable disease
- Median survival: 250-300 days
- Mitoxantrone side effects: Myelosuppression (most common), GI signs (vomiting, diarrhea), cardiotoxicity at high cumulative doses
- Maximum cumulative dose: ~80-100 mg/m² (monitor cardiac function with echocardiogram if approaching cumulative limits)
Monitoring: CBC 7-10 days post-treatment; chemistry q1-2 months
Protocol 2B: Carboplatin + Piroxicam (Alternative Second-Line)
Carboplatin is used when mitoxantrone is unavailable or not tolerated. Note: carboplatin as a single agent shows limited activity, but combination data exists.
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Carboplatin | 300 mg/m² | IV (30-min infusion) | Every 3-4 weeks |
| Piroxicam | 0.3 mg/kg | PO with food | Once daily |
- Side effects: Myelosuppression (primary toxicity), GI signs
- Dose must be adjusted in dogs with renal impairment (carboplatin is renally cleared)
THIRD-LINE / SALVAGE OPTIONS
Gemcitabine + Piroxicam
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Gemcitabine | 800 mg/m² | IV (slow infusion over 20-30 min, diluted in 0.9% NaCl) | Every 3 weeks |
| Piroxicam | 0.3 mg/kg | PO | Once daily |
- Useful as salvage; some response data in canine TCC
- Primary toxicity: myelosuppression, mild GI signs
Doxorubicin
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Doxorubicin | 30 mg/m² (dogs > 15 kg) or 1 mg/kg (dogs < 15 kg) | IV (slow infusion) | Every 3 weeks |
- Used as a salvage agent; limited TCC-specific data
- Cardiotoxicity is a major concern - cumulative lifetime dose should not exceed 180-240 mg/m²
- Baseline echo recommended before starting
Metronomic Chlorambucil (Low-intensity oral chemo)
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Chlorambucil | 4 mg/m² (or 0.1-0.2 mg/kg) | PO | Once daily (metronomic) |
- Often combined with piroxicam or meloxicam
- A recent retrospective from Hong Kong (2005-2024) included this as a studied modality
- Primary toxicity: GI signs, bone marrow suppression (less severe than conventional dosing)
- CBC monitoring every 4-6 weeks
Step 4: Supportive Care
| Indication | Drug | Dose |
|---|---|---|
| GI protection with NSAIDs | Omeprazole | 0.7-1 mg/kg PO q24h |
| GI protection (prostaglandin analog) | Misoprostol | 1-3 mcg/kg PO q8-12h |
| Urinary obstruction/stranguria | Tamsulosin (alpha-blocker) | 0.01-0.02 mg/kg PO q24h |
| Pain/stranguria | Butorphanol or buprenorphine | Per pain scoring |
| Urinary tract infection | Appropriate antibiotics (culture-guided) | As indicated |
| Urethral stent (if obstructed, not a drug) | Interventional radiology procedure | As needed |
Step 5: Monitoring Schedule
| Timepoint | Tests |
|---|---|
| Before each chemo dose | CBC, review clinical signs |
| Every 4-6 weeks | Serum chemistry (renal function especially with NSAIDs) |
| Every 6-8 weeks | Abdominal ultrasound (response assessment) |
| Every 3-4 months | Thoracic radiographs (metastasis check) |
| If mitoxantrone cumulative dose approaching limit | Echocardiogram |
Response Assessment Criteria
- Complete response (CR): Disappearance of all measurable tumor
- Partial response (PR): > 30% decrease in tumor size
- Stable disease (SD): < 30% decrease to < 20% increase
- Progressive disease (PD): > 20% increase or new lesions
If PD is documented, switch to the next line of therapy.
Key Practical Points
- Cisplatin is contraindicated in dogs for combination with piroxicam due to severe combined nephrotoxicity and GI toxicity
- Carboplatin alone has limited activity against TCC (unlike cisplatin)
- Dogs receiving sequential protocols (switching when one fails) tend to have the longest survival times - this is a "marathon" disease
- NSAIDs (piroxicam/meloxicam) should remain as a backbone throughout all lines if renal function permits
- Tumor location at the trigone is the most significant negative prognostic factor
- BRAF V595E mutation (present in ~85% of canine TCCs) is a potential targeted therapy target; trametinib (MEK inhibitor) and lapatinib are being investigated via precision medicine platforms (FidoCure)
Prognosis Summary
| Treatment | Median Survival |
|---|---|
| No treatment / surgery alone (historical) | 109 days |
| Piroxicam alone | ~244 days |
| Mitoxantrone + piroxicam | 250-300 days |
| Vinblastine + piroxicam (current preferred) | ~299 days |
| Sequential protocols | Potentially > 1-2 years |
Sources: Purdue University Comparative Oncology Program (Knapp lab), DVM360 TCC review, PMC retrospective study 2024
Clinical note: All chemotherapy dosing should be verified with a board-certified veterinary oncologist before administration. Doses may need adjustment based on individual patient weight, body condition, organ function, and prior treatment history. This protocol summary is for educational and clinical reference purposes.
This is a shared conversation. Sign in to Orris to start your own chat.